Zenas BioPharma
✦ Quant Ownership Signal how this is computed
- The number of reporting institutions increased by 10 in the most recent period (2026/Q3).
- Total institutional ownership rose 2.6 percentage points.
Ownership vs. money flow
DivergingInstitutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 119.91% +2.55pp
- Institutions
- 195 +10
- As of
- 2026/Q3 vs. prior period
Holder types
Top holders as of 2026-09-30
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 49 buys · 0 sells
| Name | Role | Stake |
|---|---|---|
| InnoCare Pharma Limited | -- | 10.32% |
| Leon Moulder | Chairperson & CEO | 0.77% |
| Wellington Management Group | -- | 10.07% |
| Hongbo Lu | Independent Director | 0.63% |
| Patricia L. Allen | Independent Director | 0.03% |
| Patrick Gerald Enright | Independent Director | 0.02% |
| Tim Xiao | Former Independent Director | 0.01% |
| Joseph Farmer | COO, President, Principal Financial Officer & Principal Accounting Officer | 0.00% |
| Jennifer Fox | Former Chief Business Officer & CFO | 0.00% |
| Jason Nunn | Independent Director | -- |
| John Orloff | Independent Director | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-31 | Christy Oliger | Independent Director | Other Derivative Acquisition | +37,000 | $31.98 |
| 2026-08-25 | InnoCare Pharma Limited | -- | Initial Statement of Beneficial | 0 | -- |
| 2026-06-14 | Leon Moulder | Chairperson & CEO | Other Derivative Acquisition | +500,000 | $18.71 |
| 2026-06-14 | Patrick Gerald Enright | Independent Director | Other Derivative Acquisition | +18,500 | $18.71 |
| 2026-06-14 | Jason Nunn | Independent Director | Other Derivative Acquisition | +18,500 | $18.71 |
| 2026-06-14 | Jennifer Fox | Former Chief Business Officer & CFO | Other Derivative Acquisition | +125,000 | $18.71 |
| 2026-06-14 | Patricia L. Allen | Independent Director | Other Derivative Acquisition | +18,500 | $18.71 |
| 2026-06-14 | Joseph Farmer | COO, President, Principal Financial Officer & Principal Accounting Officer | Other Derivative Acquisition | +175,000 | $18.71 |
| 2026-06-14 | John Orloff | Independent Director | Other Derivative Acquisition | +18,500 | $18.71 |
| 2026-06-14 | Hongbo Lu | Independent Director | Other Derivative Acquisition | +18,500 | $18.71 |
| 2026-06-14 | James Boylan | Lead Independent Director | Other Derivative Acquisition | +18,500 | $18.71 |
| 2026-06-14 | Lisa von Moltke | Head of Research & Development and Chief Medical Officer | Other Derivative Acquisition | +150,000 | $18.71 |
| 2026-05-17 | Leon Moulder | Chairperson & CEO | Open Market Acquisition | +60,000 | $16.88 |
| 2026-04-28 | Tellus BioVentures, LLC | -- | Open Market Acquisition | +60,000 | $17.62–18.02 |
| 2026-03-30 | Hongbo Lu | Independent Director | Open Market Acquisition | +3,768 | $18.63 |
| 2026-03-30 | Fairmount Funds Management LLC | -- | Private Acquisition | +150,000 | $20.00 |
| 2026-03-30 | Tellus BioVentures, LLC | -- | Open Market Acquisition | +54,000 | $18.23–19.31 |
| 2026-03-30 | Nextbio Capital Management LP | -- | Private Acquisition | +75,000 | $20.00 |
| 2026-02-12 | Patricia L. Allen | Independent Director | Open Market Acquisition | +19,860 | $23.77–26.50 |
| 2026-02-10 | Nextbio Capital Management LP | -- | Open Market Acquisition | +25,985 | $22.50 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Zenas BioPharma discussion 0 comments